- cafead Nov 11, 2021 at 11:32: AM
via AC Immune reported full data on its leading anti-tau antibody for mild-to-moderate Alzheimer’s on Wednesday afternoon, and the complete picture came in decidedly mixed.
Building on previously released results from August where the biotech’s semorinemab candidate met one of two primary endpoints, AC Immune filled in the blanks at a medical conference Wednesday. Though new analyses appeared to confirm semorinemab’s ability to slow cognitive decline on one measure, AC Immune said PET scans showed “no identifiable treatment effect” on tau distribution.
article source
Building on previously released results from August where the biotech’s semorinemab candidate met one of two primary endpoints, AC Immune filled in the blanks at a medical conference Wednesday. Though new analyses appeared to confirm semorinemab’s ability to slow cognitive decline on one measure, AC Immune said PET scans showed “no identifiable treatment effect” on tau distribution.
article source